PDCD1 and neoplasm: In addition, the receptor-ligand pair that is now the most widely targeted is PD-1 expressed by T cells, which engages with ligands expressed by APCs to attenuate CD8+ T cell activation or cancer cells, resulting in the evasion of tumor immune surveillance [1,2,4].